The stock of Charles River Laboratories International Inc. (NYSE:CRL) decreased by -$3.15 on Friday to finish at $214.46, down -1.45 percent. The last five days have seen an average of 683,280 shares of common stock traded. 8 times new highs were reached in the current year, with a fall of -$3.44. The average number of shares traded over the last 20 days was 526,265, while the average volume over the last 50 days totaled 466,620.
CRL stock appreciated 2.53% since last month. On 07/21/23, the company’s shares reached a one-month low of $197.55. The stock touched a high of $262.00 on 02/08/23, after rallying from a low of $181.22 in 52 weeks. The price of CRL stock has declined by -1.58% or -$3.44 this year, reaching a new high 8 times. Still, the stock price is down -18.15% from the 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Insider Transactions
CRL stock investors should be aware that Charles River Laboratories International Inc. (CRL) stock had its last reported insider trading activity 91 days ago on May 15. On May 15, EVP, Corp Strategy & Develop LaPlume Joseph W sold 345 shares at $190.39 each. This transaction resulted in the insider making $65,685. On May 12, LaPlume Joseph W sold 959 shares at a price of US$193.03. After the transaction, the insider now owns 24,371 shares. Director MASSARO GEORGE had earlier sold 288 shares on May 11 for $193.43 a share. The transaction was completed for $55,708.
Valuation Metrics
Charles River Laboratories International Inc. (CRL) has a trailing price-to-earnings (P/E) ratio of 22.76. Beta for the stock is 1.32. There are also a few other valuation ratios worth considering, including the trailing price-to-sales (P/S) ratio of 2.67, the price-to-book (PB) ratio of 3.38, and the price-to-cash flow ratio of 38.50.
Financial Health
For the three months ended June 29, Charles River Laboratories International Inc.’s quick ratio was 1.20, while its current ratio was 1.50, indicating its ability to pay off its debt. The company’s long-term debt to equity ratio for the quarter ending June 29 is 0.82, and the total debt to equity ratio is 0.82. As far as profitability goes, gross margin for the trailing twelve months is 37.00% percent. Charles River Laboratories International Inc.’s EBITDA margin for the year ended June 29 was 24.06%, whereas its operating margin stood at 18.50% for the same period. Based on annual data, it had gross profit of $1.46 billion and revenue of $3.98 billion.
Investors will also look at the performance of the company’s management in order to determine the potential profitability of their investment. CRL’s return on assets (ROA) during the last 12 months has been 6.40%. There was a 9.50% return on investment (ROI) in the past year. In the meantime, the return on equity (ROE) for the last 12 months was 16.20%.
Earnings Surprise
According to Charles River Laboratories International Inc.’s quarterly financial report for the quarter that ended June 29. A higher net income was reported in the quarter under review than the previous quarter. Net income for the quarter came in at $1.06 billion, while revenues rose by 8.19% to $1.03 billion. It was predicted that Charles River Laboratories International Inc.’s quarterly earnings would be $2.69, but it ended up being $2.64, beating the consensus by 1.90%. EBITDA was $242.62 million for the quarter. At the end of Charles River Laboratories International Inc.’s most recent quarter ended June 29, its liabilities totaled 4.51 billion, while its total debt was $3.08 billion. Equity owned by shareholders amounts to $51.27 million.
Technical Picture
Here’s a quick look at Charles River Laboratories International Inc.’s (CRL) price momentum from a technical perspective. As of 11 August, the RSI 9-day stood at 59.76%, suggesting the stock is Neutral, with a 32.48% historical volatility rate.
The stochastic %K and %D were 84.79% and 73.27% respectively, while the average true range (ATR) was 5.79. Based on the 14-day stochastic reading of 75.45%, the RSI (14) reading is 57.90%. On the 9-day MACD Oscillator, the stock is at 6.72, and the 14-day reading is at 6.26.
Analyst Ratings
Charles River Laboratories International Inc. (NYSE: CRL) was downgraded by Citigroup to a a Neutral rating in its latest research report. The stock was previously rated as a a Buy. Analysts have assigned Charles River Laboratories International Inc. (CRL) an Overweight rating. CRL is a stock that is recommended for selling by 0 brokerage firms, while 3 companies recommend holding. The stock is underweighted by 0 analysts. Among the analysts who rate the stock, 3 rates it overweight and 10 others recommend it as a buy.
What is CRL’s price target for the next 12 months?
The current consensus forecast for the stock is between $207.00 and $280.00, with a median target price of $250.00. In analyzing these forecasts, the average price target given by analysts for Charles River Laboratories International Inc. (CRL) is $248.77.
